Determine the Effect of AZD3161,injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Study identifier:D3780C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers

Medical condition

Peripheral neuropathic pain

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3161, Lidocaine, AZD3161 Placebo

Sex

All

Actual Enrollment

26

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Dec 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria